Advanced Search
CHENG Jinjian, YANG Hua, LU Heming, HAO Yanrong, LU Zhiping, CHEN Jiaxin. Analysis of Body Weight Loss and Influence Factors During Intensity-modulated Radiotherapy for Patients with Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2013, 40(08): 767-771. DOI: 10.3971/j.issn.1000-8578.2013.08.010
Citation: CHENG Jinjian, YANG Hua, LU Heming, HAO Yanrong, LU Zhiping, CHEN Jiaxin. Analysis of Body Weight Loss and Influence Factors During Intensity-modulated Radiotherapy for Patients with Nasopharyngeal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2013, 40(08): 767-771. DOI: 10.3971/j.issn.1000-8578.2013.08.010
shu

Analysis of Body Weight Loss and Influence Factors During Intensity-modulated Radiotherapy for Patients with Nasopharyngeal Carcinoma

  • 1.Department of Radiation Oncology, Cancer Center, People's Hospital of Guangxi Zhuang Autonomous Region，Nanning 530021，China；2.School of Pharmaceutical Sciences，Guangxi Medical University

More Information
  • Received Date: August 05, 2012
  • Revised Date: October 09, 2012
    Graphical Abstract
    • Abstract
  • Objective To investigate body weight loss and influence factors during intensity-modulated radiotherapy (IMRT) in patients with nasopharyngeal carcinoma (NPC). Methods To explore body weight and BMI variation and influence factors，body weight and body mass index (BMI) change analysis were done retrospectively for 57 NPC patients during IMRT. Results In 57 NPC patients treated by IMRT, the pre-radiotherapy and post-radiotherapy average body weight were （60.4±9.4）kg and （55.1±8.7）kg (P=0.0025), body weight loss ranged from 17 kg to-0.5 kg，and average BMI of pre-radiotherapy and post-radiotherapy were （22.8±3.5）kg/m2，（20.8±3.1）kg/m2 (P=0.0017), ranged from 6.0 kg/m2 to -0.2 kg/m2，respectively. To the end of radiotherapy，93.0% patients lost weight at different levels, the mean percentage of weight loss was 8.4% and ranged from 23.4%to -0.7%, 35.1% patients lost weight over 10% and 68.4% patients lost weight over 5.0%. Univariate multi-factor analysis of variance showed that the WHO pathological grade, AJCC6th stage, performance status (PS), concurrent chemotherapy and late course accelerated hyperfractionated radiotherapy (LCAFR) had no statistical influence on body weight and BMI loss, but patients with age older than 50 years or BMI greater than 25 kg/m2 or body weight more than 60 kg lost body weight and BMI more than others (P<0.05). Linear regression analysis showed that average radiation dose weekly and the average body weight weekly were significantly negatively correlated (R2=-0.996，P<0.001). Conclusion Body weight loss is widespread in NPC patients during IMRT. The age, pre-radiotherapy body weight and BMI, radiation dose maybe have more impact on body weight and BMI loss significantly rather than the gender，WHO pathological grade, AJCC6thstage, performance status, concurrent chemotherapy and late course accelerated hyperfractionated radiotherapy in NPC patients with IMRT.
    • FullText(HTML)
    • References (14)
  • [1]
    Yi JL, Gao L, Xu GZ, et al. Proceedings of nasopharyngeal carcinoma with intensity-modulated radiotherapy.Proceedings of the 6th Chinese national nasopharyngeal cancer conference[C]. 2010: 37-8. [易俊林, 高黎, 徐国镇，等. 鼻咽癌调强放射治疗结果更新. 第六届全国鼻咽癌学术大会论文汇编[C]. 2010: 37-8.]
    [2]
    Xu L, Pan J, Wu J,et al. Factors associated with overall survival in 1706 patients with nasopharyngeal carcinoma: significance of intensive neoadjuvant chemotherapy and radiation break [J]. Radiother Oncol,2010,96(1): 94-9.
    [3]
    Fang FM, Tsai WL, Chen HC, et al. Intensity-modulated or conformal radiotherapy improves the quality of life of patients with nasopharyngeal carcinoma: comparisons of four radiotherapy techniques [J]. Cancer,2007, 109(2): 313-21.
    [4]
    Lai SZ, Li WF, Chen L, et al. How does intensity-modulated radiotherapy versus conventional two-dimensional radiotherapy influence the treatment results in nasopharyngeal carcinoma patients? [J]. Int J Radiat Oncol Biol Phys,2011,80（3）：661-8.
    [5]
    Ng K, Leung SF, Johnson PJ, et al. Nutritional consequences of radiotherapy in nasopharynx cancer patients [J]. Nutr Cancer, 2004, 49(2): 156-61.
    [6]
    Oates JE, Clark JR, Read J, et al. Prospective evaluation of quality of life and nutrition before and after treatment for nasopharyngeal carcinoma [J]. Arch Otolaryngol Head Neck Surg,2007, 133(6): 533-40.
    [7]
    Cheng JJ, Yang H, Chen JX, et al. The impacts of intensity-modulated radiotherapy and chemotherapy on nutritional status of patients with nasopharyngeal carcinoma[J]. Guangdong Yi Xue,2011, 32(17): 2336-8. [程金建, 杨华, 陈甲信, 等.调强放疗及化疗对鼻咽癌患者营养状况的影响[J]. 广东医学, 2011, 32(17): 2336-8.]
    [8]
    Unsal D, Mentes B, Akmansu M, et al. Evaluation of nutritional status in cancer patients receiving radiotherapy: a prospective study [J]. Am J Clin Oncol,2006, 29(2):183-8.
    [9]
    Ravasco P, Monteiro-Grillo I, Marques Vidal P, et al. Impact of nutrition on outcome: a prospective randomized controlled trial in patients with head and neck cancer undergoing radiotherapy [J]. Head Neck,2005, 27(8):659-68.
    [10]
    Mueller C, Compher C, Ellen DM, et al. A.S.P.E.N. clinical guidelines: Nutrition screening, assessment, and Intervention in adults [J]. JPEN J Parenter Enteral Nutr,2011, 35(1): 16-24.
    [11]
    Bahl M, Siu LL, Pond GR, et al. Tolerability of the Intergroup 0099 (INT 0099) regimen in locally advanced nasopharyngeal cancer with a focus on patients' nutritional status [J]. Int J Radiat Oncol Biol Phys, 2004, 60 (4): 1127-36.
    [12]
    Zhao L, Wan Q, Zhou Y, et al. The role of replanning in fractionated intensity modulated radiotherapy for nasopharyngeal carcinoma [J]. Radiother Oncol,2011, 98(1): 23-7.
    [13]
    Wang X, Lu J, Xiong X, et al. Anatomic and dosimetric changes during the treatment course of intensity-modulated radiotherapy for locally advanced nasopharyngeal carcinoma[J]. Med Dosim,2010, 35(2):151-7.
    [14]
    Wang W, Yang H, Hu W, et al. Clinical study of the necessity of replanning before the 25th fraction during the course of intensity-modulated radiotherapy for patients with nasopharyngeal carcinoma [J]. Int J Radiat Oncol Biol Phys,2010, 77(2): 617-21.
    • Related Articles

  • Related Articles

    [1]HU Lili, YIN Yanjun, ZHONG Wenjuan, QIU Feng. miR-200c Enhances Sensitivity of Lung Cancer Cell A549 to Paclitaxel and Gefitinib and Related Mechanism[J]. Cancer Research on Prevention and Treatment, 2015, 42(08): 760-764. DOI: 10.3971/j.issn.1000-8578.2015.08.003
    [2]FAN Bei, LI Hongxia, WU Yumei, ZHAO Qun, DENG Xiaohong. Biological Characteristics of Paclitaxel-resistance Ovarian Cancer Cell Lines and Cryopreservation Methods[J]. Cancer Research on Prevention and Treatment, 2015, 42(04): 334-339. DOI: 10.3971/j.issn.1000-8578.2015.04.004
    [3]QU Yuying, YUE Guijuan, LI Jiansheng, HUANG Hui. Effect of Jinlong Capsules on Reversing Paclitaxel-resistance Vincritine-resistance and Enhancing Sensitivity in Human Cancer Cell Lines[J]. Cancer Research on Prevention and Treatment, 2014, 41(08): 884-887. DOI: 10.3971/j.issn.1000-8578.2014.08.006
    [4]ZHANG Jinlu, ZHANG Xiaohong, WANG Yurong, HE Chao, WU Jihui, LUO Cheng. MAGEA10 Expression in Human Lung Cancer A549 Cells Influenced by Viili Polysaccharides[J]. Cancer Research on Prevention and Treatment, 2013, 40(07): 635-638. DOI: 10.3971/j.issn.1000-8578.2013.07.002
    [5]WU Jun, WEN Min, ZHANG Hai-tao. Galangin Induces Apoptosis on Lung Cancer A549 Cells[J]. Cancer Research on Prevention and Treatment, 2011, 38(11): 1228-1231. DOI: 10.3971/j.issn.1000-8578.2011.11.003
    [6]DENG Chao, HE Yan, HU Chun-hong. Efficacy and Safety of Paclitaxel Liposomes in Treatment of 40 Patients with NSCLC[J]. Cancer Research on Prevention and Treatment, 2011, 38(03): 315-318. DOI: 10.3971/j.issn.1000-8578.2011.03.020
    [7]XIAO Yu-jie, WANG Hong-mei, HAN Zheng-xiang, GAO Xiang-yang, PEI Dong-sheng, ZENG Ling-yu, DU Xiu-ping. Reverse Paclitaxel Resistance by Silencing stathmin and mdr1 in Ovarian Cancer Cells[J]. Cancer Research on Prevention and Treatment, 2011, 38(03): 243-246. DOI: 10.3971/j.issn.1000-8578.2011.03.001
    [8]LU Hong, FAN Qing-xia, WANG Rui-lin. Apoptosis in Paclitaxel Resistant Cell Line Ec9706/P-1 of Human Esophageal Carcinoma[J]. Cancer Research on Prevention and Treatment, 2010, 37(12): 1356-1359. DOI: 10.3971/j.issn.1000-8578.2010.12.006
    [9]LI Ling, CHEN Fu-chun, CHEN Hong-lei, PAN Qi, DIAO Lu-ming. Effect of Combination of Docetaxel with Curcumin on Proliferation and Apoptosis of Human Lung Adenocarcinoma A549 Cell[J]. Cancer Research on Prevention and Treatment, 2010, 37(06): 617-620. DOI: 10.3971/j.issn.1000-8578.2010.06.003
    [10]DONG Jun-hong, WANG Zhen-ming, FU Xin-hua, WANG Shou-xun, HUANG Huan-sheng. Effects of Silence survivin by RNAi on Apoptosis of A549 Cells and on Sensitivity of A549 Cells to Paclitaxel[J]. Cancer Research on Prevention and Treatment, 2010, 37(03): 266-268. DOI: 10.3971/j.issn.1000-8578.2010.03.006

Catalog

    Get Citation
    PDF
    XML
    Article views (2304) PDF downloads (473) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Download Center

    Links

    Contact Us

    Address：116 Zhuodaoquan South Road,
    Hongshan District, Wuhan（430079）

    Tel：027－87670126

    Email：zlfzyjzz@vip.163.com

    This work is licensed under a Creative Commons Attribution 3.0 License.

    Email Alert RSS
    Total visits：11733850 Visits today：1583

    Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return